JY BioMed ADC Technology Wins Innovation Award, Eyes Global Licensing. Taiwan's JY BioMed has earned the 22nd National Innovation Award for its HCAb-ADC platform, secured FDA Orphan Drug Designation for pancreatic cancer, and published findings in Cancer Letters, as it advances international licensing partnerships across lung, pancreatic, and colorectal cancers.